Question 1

Is ZTS stock overvalued right now?

Accepted Answer

Our multi-model fair value estimate of $85.67 suggests ZTS may be undervalued by approximately 21.0% at the current price of $70.82.

Question 2

What is ZTS fair value based on current fundamentals?

Accepted Answer

Our fair value estimate for ZTS is $85.67, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

Question 3

How risky is ZTS compared with other stocks?

Accepted Answer

Risk profile for ZTS: a beta of 0.73 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.

Question 4

Is ZTS still growing?

Accepted Answer

Latest trailing metrics show revenue contraction of 0.2% and earnings growth of 1.2%. Profit margins are 27.7%.

Question 5

What do analysts think about ZTS?

Accepted Answer

Analyst consensus target is $96.00, implying 35.6% upside. The street recommendation is "buy".

Question 6

Does ZTS pay a dividend?

Accepted Answer

Yes. ZTS currently offers a dividend yield of 3.0%.

Question 7

What could change the investment case for ZTS?

Accepted Answer

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

ZTS Stock Analysis

Phasakorn Traklang (Peach) — ผู้ก่อตั้ง